Kalaris Therapeutics (KLRS) Competitors $3.89 -0.39 (-9.11%) As of 09/12/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsOwnershipSEC FilingsShort InterestTrendsBuy This Stock KLRS vs. FDMT, ALT, ALDX, FHTX, LRMR, CTNM, DMAC, AMRN, TECX, and KRROShould you be buying Kalaris Therapeutics stock or one of its competitors? The main competitors of Kalaris Therapeutics include 4D Molecular Therapeutics (FDMT), Altimmune (ALT), Aldeyra Therapeutics (ALDX), Foghorn Therapeutics (FHTX), Larimar Therapeutics (LRMR), Contineum Therapeutics (CTNM), DiaMedica Therapeutics (DMAC), Amarin (AMRN), Tectonic Therapeutic (TECX), and Korro Bio (KRRO). These companies are all part of the "pharmaceutical products" industry. Kalaris Therapeutics vs. Its Competitors 4D Molecular Therapeutics Altimmune Aldeyra Therapeutics Foghorn Therapeutics Larimar Therapeutics Contineum Therapeutics DiaMedica Therapeutics Amarin Tectonic Therapeutic Korro Bio 4D Molecular Therapeutics (NASDAQ:FDMT) and Kalaris Therapeutics (NASDAQ:KLRS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, risk and valuation. Which has preferable earnings and valuation, FDMT or KLRS? Kalaris Therapeutics has lower revenue, but higher earnings than 4D Molecular Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio4D Molecular Therapeutics$40K7,950.68-$160.87M-$3.53-1.93Kalaris TherapeuticsN/AN/A-$58.77MN/AN/A Do insiders & institutionals believe in FDMT or KLRS? 99.3% of 4D Molecular Therapeutics shares are held by institutional investors. Comparatively, 66.1% of Kalaris Therapeutics shares are held by institutional investors. 9.6% of 4D Molecular Therapeutics shares are held by insiders. Comparatively, 75.0% of Kalaris Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Is FDMT or KLRS more profitable? Kalaris Therapeutics has a net margin of 0.00% compared to 4D Molecular Therapeutics' net margin of -594,375.81%. 4D Molecular Therapeutics' return on equity of -40.15% beat Kalaris Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets 4D Molecular Therapeutics-594,375.81% -40.15% -36.43% Kalaris Therapeutics N/A -81.02%-65.15% Does the media favor FDMT or KLRS? In the previous week, 4D Molecular Therapeutics had 5 more articles in the media than Kalaris Therapeutics. MarketBeat recorded 7 mentions for 4D Molecular Therapeutics and 2 mentions for Kalaris Therapeutics. 4D Molecular Therapeutics' average media sentiment score of 1.25 beat Kalaris Therapeutics' score of 0.95 indicating that 4D Molecular Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 4D Molecular Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kalaris Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, FDMT or KLRS? 4D Molecular Therapeutics has a beta of 2.86, meaning that its share price is 186% more volatile than the S&P 500. Comparatively, Kalaris Therapeutics has a beta of 0.37, meaning that its share price is 63% less volatile than the S&P 500. Do analysts rate FDMT or KLRS? 4D Molecular Therapeutics presently has a consensus price target of $30.40, indicating a potential upside of 346.40%. Kalaris Therapeutics has a consensus price target of $3.00, indicating a potential downside of 22.88%. Given 4D Molecular Therapeutics' higher possible upside, analysts clearly believe 4D Molecular Therapeutics is more favorable than Kalaris Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 4D Molecular Therapeutics 1 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.64Kalaris Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 3.00 Summary4D Molecular Therapeutics beats Kalaris Therapeutics on 9 of the 14 factors compared between the two stocks. Get Kalaris Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KLRS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KLRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KLRS vs. The Competition Export to ExcelMetricKalaris TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$80.05M$3.20B$5.87B$10.14BDividend YieldN/A2.30%5.68%4.59%P/E RatioN/A21.1774.5225.93Price / SalesN/A476.06548.33126.97Price / CashN/A46.6837.5660.44Price / Book0.179.6112.166.29Net Income-$58.77M-$53.29M$3.28B$270.77M7 Day Performance-15.80%0.28%0.87%3.88%1 Month Performance70.61%5.73%4.96%4.88%1 Year PerformanceN/A10.52%60.74%26.01% Kalaris Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KLRSKalaris Therapeutics1.866 of 5 stars$3.89-9.1%$3.00-22.9%N/A$80.05MN/A0.00110News CoveragePositive NewsFDMT4D Molecular Therapeutics2.6667 of 5 stars$7.27+10.0%$30.40+318.2%-57.2%$339.52M$33K-2.06120News CoverageALTAltimmune2.7068 of 5 stars$3.78+6.2%$17.40+360.3%-48.7%$333.61M$20K-3.2050ALDXAldeyra Therapeutics2.1745 of 5 stars$5.56+0.5%$9.50+70.9%-12.9%$333.02MN/A-6.5410Positive NewsFHTXFoghorn Therapeutics2.7484 of 5 stars$5.77+7.1%$10.67+84.9%-41.6%$326.18M$24.17M-4.85120Positive NewsLRMRLarimar Therapeutics2.7621 of 5 stars$3.94+1.8%$18.43+367.7%-45.7%$326.15MN/A-2.5330CTNMContineum Therapeutics2.6789 of 5 stars$11.50+4.6%$22.75+97.8%-31.6%$322.48M$50M-5.2331Short Interest ↑DMACDiaMedica Therapeutics2.2293 of 5 stars$6.14+14.3%$12.33+100.9%+65.3%$317.37MN/A-8.9020Positive NewsAnalyst UpgradeHigh Trading VolumeAMRNAmarin0.608 of 5 stars$15.33+2.0%$12.00-21.7%+29.0%$317.07M$219.36M-4.18360TECXTectonic Therapeutic3.207 of 5 stars$16.80-2.7%$80.29+377.9%+1.3%$314.36MN/A-4.16120Positive NewsKRROKorro Bio2.2306 of 5 stars$33.18+18.2%$86.83+161.7%-23.9%$311.59M$2.27M-3.4070Positive NewsHigh Trading Volume Related Companies and Tools Related Companies FDMT Competitors ALT Competitors ALDX Competitors FHTX Competitors LRMR Competitors CTNM Competitors DMAC Competitors AMRN Competitors TECX Competitors KRRO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KLRS) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kalaris Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kalaris Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KLRS Stock Alerts